Abstract
Tower Microneedle was developed with minimal ocular tissue damages even reflux, while no study was reported with intravitreal injection of ophthalmic drug via Tower Microneedle into the eye. Intravitreal injection of anti-vascular endothelial growth factor antibodies via the Tower Microneedle or a 30-G hypodermic needle was performed 1 week after argon laser irradiation into the retina of the mouse models. Less bleb formation was occurred with Tower Microneedle than 30-G hypodermic needle, while both needles led to comparable degrees of anti-angiogenesis in the retina after intravitreal injection of anti-vascular endothelial growth factor antibodies over 100 ng/μL concentration. Conclusively, the Tower Microneedle can deliver anti-vascular endothelial growth factor antibody into the posterior segment of the eye with minimal bleb formation after intravitreal injection.
Original language | English |
---|---|
Pages (from-to) | 232-238 |
Number of pages | 7 |
Journal | Biochip Journal |
Volume | 9 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2015 Sep 28 |
Bibliographical note
Publisher Copyright:© 2015, The Korean BioChip Society and Springer-Verlag Berlin Heidelberg.
All Science Journal Classification (ASJC) codes
- Biotechnology
- Bioengineering
- Biomedical Engineering
- Electrical and Electronic Engineering